Moderna, Merck melanoma vaccine clears Phase 3 trial goal
What's next: The companies plan talks with regulators within months as they pursue approval for the personalized shot with Keytruda.
Series
What's next: The companies plan talks with regulators within months as they pursue approval for the personalized shot with Keytruda.